CODEBREAK 100 Study Breakthrough as Amgen’s Sotorasib Zaps Lung Cancer Tumors in Patients with Specific Genetic Error

CODEBREAK 100 Study Breakthrough as Amgen’s Sotorasib Zaps Lung Cancer Tumors in Patients with Specific Genetic Error

An NYU Langone, Perlmutter Cancer Center researcher discovered that Amgen’s sotorasib reduced tumors in patients with non-small cell lung cancer (NSCLC) who also happened to be harboring a specific change, or mutation, in the DNA code for KRAS, known as p.G12C. The results of this study were published in the New England Journal of Medicine and simultaneously presented at the American Society of Clinical Oncology (ASCO) annual meeting. As it turns out, the researchers observed that tumors shrunk in 37.1% of the patients in Phase 2 CODEBREAK 100 study by at least 30% ,which was termed an “objective response.” Moreover, an impressive 82% of all patients treated experienced at least some slowing of tumor growth also known as “disease control.” This study, led by Perlmutter Cancer Center investigators from NYU Langone, but also Washington University School of Medicine, MD Anderson Cancer Center, and Memorial Sloan Kettering Cancer Center, involved 126 patients that received daily oral sotorasib, a KIRASG12C inhibitor that was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with KRAS G12C-mutated NSCLC. Sotorasib, recently approved, n...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee